Skip to main content
main-content

01.12.2011 | Case report | Ausgabe 1/2011 Open Access

Journal of Medical Case Reports 1/2011

Henoch Schönlein purpura associated with pulmonary adenocarcinoma

Zeitschrift:
Journal of Medical Case Reports > Ausgabe 1/2011
Autoren:
Daiki Mifune, Satoshi Watanabe, Rie Kondo, Yoko Wada, Hiroshi Moriyama, Hiroshi Kagamu, Hirohisa Yoshizawa, Takafumi Tetsuka, Asako Matsuyama, Kaoru Ito, Ichiei Narita
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1752-1947-5-226) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

DM wrote the manuscript. SW was responsible for the manuscript concept and final corrections to the manuscript. YW and IN analyzed and interpreted our patient data regarding the renal disease. AM and KI performed the histological examination of the skin. RK, HM, HK, HY and TT participated in patient care and collected data. All authors have read and approved the final manuscript.

Introduction

Henoch-Schönlein Purpura (HSP) is a systemic vasculitis that involves the small vessels, most notably those in the skin, gastrointestinal tract and glomeruli, and is accompanied by arthralgia or arthritis [1]. HSP occurs commonly in children but can also affect adults [2]. Although the exact cause of HSP remains unknown, malignancy has been reported as a causative factor [35]. This report illustrates a rare case of HSP associated with pulmonary adenocarcinoma.

Case Presentation

A 61-year-old Japanese man presented for examination after an abnormal lung shadow was detected during population-based radiological screening. He was a current smoker with a 41 pack-year smoking history. Chest computed tomography (CT) showed a mass measuring 60 × 50 mm in the left upper lobe, with small nodules in both lung fields and left pleura, and mediastinal and subclavicular lymphadenopathy (Figure 1). Bronchoscopy revealed stenosis of the left B3 bronchus with mucosal abnormalities at points from which biopsy specimens were obtained. Cerebral magnetic resonance imaging (MRI) demonstrated multiple brain metastases. The final oncological diagnosis was a stage IV adenocarcinoma (T4N3M1b) without epidermal growth factor receptor gene mutation. After stereotactic radiosurgery for brain metastases, carried out in another hospital, our patient was referred to us to receive chemotherapy.
On admission, our patient had progressive abdominal pain, diarrhea and purpuric rash on the legs, which had developed over the previous month. He was not taking any medication. The abdomen was soft and flat with minor tenderness. Palpable purpura was present on both legs. His Eastern Cooperative Oncology Group performance status was 1. His hematologic and blood chemical values were: white blood cell count of 9530/mm3, a hemoglobin concentration of 11.2 g/dL, an erythrocyte sedimentation rate of 83 mm/hour, 6.52 mg/dL serum C-reactive protein, >55U/mL CH50, 132 mg/dL C3, 37.7 mg/dL C4, 10.7 μg/dL D-dimer and 694 mg/dL fibrinogen (normal 160-400). Urine analysis showed proteinuria of 1.28 g/day and hematuria of >100 erythrocytes per high-power field. Stool examination for occult blood was positive. The findings were normal or negative for platelet count, prothrombin time, activated partial thromboplastin time, transaminases, creatinine, antistreptolysin O, rheumatoid factor (RF), antinuclear antibody (ANA), IgA, antineutrophil cytoplasmic antibody (ANCA), cryoglobulin, rapid plasma regain, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody and human immunodeficiency virus antibody. Blood, urine and sputum cultures were negative. Abdominal CT revealed diffuse swelling and thickening of the small intestine walls and an absence of metastases (Figure 2). Enteroscopy demonstrated multiple erosions and ulcers of the intestine. A biopsy taken from the intestinal mucus showed non-specific chronic inflammation without evidence of vasculitis. On histopathologic examination of the palpable purpura, vasculitis was seen, with infiltration of polymorphonuclear cells into the vessel walls of the subpapillar plexus under the epidermis (Figure 3AB). Immunofluorescent studies of the biopsy specimen revealed deposition of IgA without C3 in superficial blood vessels (Figure 3C).
Our patient was diagnosed with HSP. Treatment with prednisolone 0.8 mg/kg/day was initiated following deterioration of renal function, as evidenced by a drop in creatinine clearance from 82 mL/min at the time of admission to 27 mL/min before starting prednisolone. The clinical features of HSP, including abdominal pain and skin rash, resolved within a week. Creatinine clearance improved to 46 mL/min four weeks after the start of steroid treatment. Prednisolone was tapered and maintained at 0.6 mg/kg/day. Our patient received two cycles of chemotherapy with gemcitabine 1000 mg/m2 administered on days one and eight of each three-weeks cycle. HSP was well controlled, and no other adverse events were observed during chemotherapy. Two months after of the start of chemotherapy, the patient developed rapidly progressing dyspnea and hypoxia. Chest CT and cardiac ultrasonography identified tumor invasion of the pericardium and massive pericardial effusion. Cytological examination of the pericardial effusion revealed adenocarcinoma cells. Our patient was diagnosed with heart failure due to cardiac tamponade, and twice underwent surgical drainage of the pericardial effusion. His general condition gradually deteriorated with disease progression, and he died three months after the onset of HSP.

Discussion

HSP is a systemic vasculitis with IgA-dominant immune deposits affecting small vessels, especially those in the skin, gastrointestinal tract and kidney, and is accompanied by arthralgia or arthritis [1]. HSP occurs more commonly in children. The clinical presentation of HSP is more severe in adults than in children, and the outcome in adults is relatively poor [2].
The diagnostic criteria for HSP by the American College of Rheumatology are: palpable purpura, patient aged ≤20 years; bowel angina, and granulocytes in the walls of small arterioles or venules seen on biopsy. The presence of two or more of these criteria has a sensitivity and specificity of 87.1% and 87.7%, respectively [6]. Our case met three of the four criteria, with the exception of age. Other vasculitides were highly unlikely because markers for other systemic vasculitides (antistreptolysin O, RF, ANA, ANCA, cryoglobulin, rapid plasma regain, HBsAg, HCV) were all negative. Moreover, immunofluorescent studies of the biopsied skin specimen showed IgA deposition in blood vessels. These findings confirmed HSP. Novák et al. reported that vasculitic endoscopic lesions had been documented in only some patients with HSP with abdominal symptoms [7]. Their findings may explain the finding in our patient's intestinal specimen of non-specific chronic inflammation without vasculitis.
The occurrence of vasculitis in patients with malignancy has been estimated at one in 1800 for hematological malignancies and one in 80,800 for solid tumors [3]. HSP represents only 5% of vasculitis cases associated with malignancy [4]. Although hematological malignancies were more common than solid tumors in all types of vasculitis, solid tumors were more common in association with HSP [5]. Mitsui et al. reported that 23 of 53 patients with HSP (43.4%) aged >40 years had underlying malignancies [8]. The etiology of HSP remains obscure, and various triggers, including bacterial or viral infections, foods and drugs, have been hypothesized. Adult patients with HSP should be investigated for malignancies, especially in the absence of these triggers [8].
Lung cancer is the most common solid malignancy associated with HSP. Twelve cases of lung cancer presenting with HSP have been reported to date, including this one (Table 1) [918]. Mean patient age was 64.9 years (range 50-79 years) and all patients were men. The most common lung-cancer histological diagnoses were squamous cell (n = 7), adenocarcinoma (n = 3) and small cell (n = 2). In six cases, the diagnosis of both processes was simultaneous, and in four cases, HSP antedated lung cancer by an average of 9.2 months (range five-22 months). Lung cancer did not antedate HSP in any of the cases. All patients had palpable purpura and renal involvement, 55% of patients had gastrointestinal symptoms and 64% had joint involvement. In the case reported here, there were no identifiable triggers for the onset of HSP other than the malignancy itself. The diagnosis of malignancy and the onset of HSP occurred at the same time, therefore we believe that the HSP was associated with the malignancy.
Table 1
Patients with Henoch-Schönlein purpura and lung cancer.
Author
Histology
Occurrence of vasculitis in relation to tumor
HSP therapy
Malignancy therapy
Cairns [9]
Squamous
eight months before tumor
Not done
None
 
Squamous
Synchronousa
Not done
Surgical resection
Maurice [10]
Squamous
Synchronous
Not done
Surgical resection
Mitchell [11]
Squamous
22 months before tumor
Prednisone + azathioprine
Surgical resection
Pfitzenmeyer [12]
Squamous
six months before tumor
Not done
None
Gutiérrez [13]
Squamous
Synchronous
Not available
Not available
Frigui [14]
Squamous
six months before tumor
Methylprednisolone pulses, prednisone
Chemotherapy, radiotherapy
Blanco R [15]
Small cell
Synchronous
Not done
Chemotherapy
Ponge T [16]
Small cell
eight months before tumor
Not done
Chemotherapy
Weiler-Bisig [17]
Adenocarcinoma
five months before tumor
Prednisolone
Chemotherapy
Salon [18]
Adenocarcinoma
Synchronous
Prednisone + intravenous gammaglobulins
Surgical resection
Present case
Adenocarcinoma
Synchronous
Prednisolone
Chemotherapy
aSynchronous: within 1 month of cancer diagnosis.
Treatment for patients with HSP and lung cancer is also summarized in Table 1. Therapies for lung cancer induced remission of HSP in some cases [9, 10, 15, 16], whereas other case reports indicated that corticosteroid therapy was required for improvement of HSP [11, 14, 17, 18], as with our case. Our patient had an Eastern Cooperative Oncology Group performance status of 1, and after treatment of the HSP to correct the progressive renal insufficiency, there was no contraindication for chemotherapy. Corticosteroid therapy obviously contributed to the improvement of the HSP and safe chemotherapy. Unfortunately, the patient did not respond to chemotherapy and died from causes associated with the underlying cancer. Mitsui et al. found a correlation between the development of HSP and poor prognosis of malignancies [8]. They reported that seven of nine patients with HSP and malignancies exhibited new metastatic lesions or died of cancer within one-32 months from the onset of HSP.

Conclusion

We report a rare case of HSP associated with non-small cell lung cancer. To the best of our knowledge, this is only the third case of HSP presenting with pulmonary adenocarcinoma. Although the optimum treatment of HSP with malignancy remains unclear, corticosteroid therapy dramatically improved our patient's clinical symptoms, and contributed to the management of his lung cancer.

Consent

Written informed consent was obtained from the patient's spouse for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

DM wrote the manuscript. SW was responsible for the manuscript concept and final corrections to the manuscript. YW and IN analyzed and interpreted our patient data regarding the renal disease. AM and KI performed the histological examination of the skin. RK, HM, HK, HY and TT participated in patient care and collected data. All authors have read and approved the final manuscript.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

e.Med Allgemeinmedizin

Kombi-Abonnement

Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.​​​​​​​​​​​​​​

Zusatzmaterial
Authors’ original file for figure 1
13256_2010_1647_MOESM1_ESM.pdf
Authors’ original file for figure 2
13256_2010_1647_MOESM2_ESM.pdf
Authors’ original file for figure 3
13256_2010_1647_MOESM3_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2011

Journal of Medical Case Reports 1/2011 Zur Ausgabe